, /PRNewswire/ — Amphix Bio, a company developing a new class of regenerative medicine therapies, announced that it has secured a $1M Small Business Innovation Research (SBIR) Phase II grant from the National Science Foundation (NSF) to scale up manufacturing methods for its platform technology. The platform is based on supramolecular peptide therapeutics that signal the patient’s own cells to initiate regenerative processes.
Amphix Bio receives grant funding to scale-up manufacturing of new regenerative medicine therapies
The manufacturing technology developed with the grant funds will be used to produce an off-the-shelf implant for spinal fusion surgeries. This product was recently designated as a Breakthrough Device by the FDA for treating back pain caused by degenerative disc disease. In its Phase I project, Amphix Bio developed new manufacturing methods for its bone regeneration therapy and created a moldable, putty-like formulation that demonstrated efficacy in large animal models. The goals of the Phase …